Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma

As a multi-kinase inhibitor, sorafenib is beneficial in around 30% of hepatocellular carcinoma (HCC) patients; however, HCC patients develop acquired drug resistance quickly. Clinical benefits of sorafenib, in combination with transarterial chemoembolization (TACE), radiotherapy, and other chemodrug...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xuran, Xia, Wei, Chen, Lin, Wu, Chuan Xing, Zhang, Cathy C., Olson, Peter, Wang, Xiao Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201862/
https://www.ncbi.nlm.nih.gov/pubmed/30405889
http://dx.doi.org/10.18632/oncotarget.26209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201862/
https://www.ncbi.nlm.nih.gov/pubmed/30405889
http://dx.doi.org/10.18632/oncotarget.26209

Ejemplares similares